Abcuroincis A Clinical Stage Biotechnology Company Based In Newtonmassachusettsfounded In 2015The Company Specializes In Developing Precision Therapies For Autoimmune Diseases And Cancer By Targeting Cytotoxic T Cells And Natural Killernkcellsabcuro S Innovative Approach Focuses On Modulating These Immune Cells To Address Tissue Damage In Autoimmune Disorders And Enhance Immune Responses In Oncology The Company S Lead Productabc008Ulviprubart Is A First In Class Monoclonal Antibody Currently In Phase 2 3 Trials For Inclusion Body Myositisa Rare Autoimmune Diseaseabcuro Also Has Preclinical Oncology Programs Aimed At Improving Nk And T Cell Activity For Conditions Like Multiple Myelomathe Company Has Secured Significant Fundingraising $155 Million In Series B Financing In 2023Which Supports Its Ongoing Clinical Initiatives And Research Effortsabcuro Is Committed To Addressing Diseases With Limited Treatment Options Through Its Targeted Therapies
No conferences found for this company.
| Company Name | Abcuro Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
